drugset

drugset / Trial / NCT00635856

Open Label Trial to Assess Iressa in Prostate Cancer Patients

NCT00635856 ↗

Phase 2 Completed 100 enrolled AstraZeneca

NaSingle-groupOpen-label

Summary

A study to assess the activity of Iressa in patients who's prostate cancer has recurred, and who have rising PSA levels

Timeline

Start: 2001-05
Primary completion: —
Completion: 2003-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gefitinib	Small molecule	—	—

Indications